DeepVerge’s AGM of 26 July 2021 provided its Board with an ideal platform to highlight both the Group’s transformational past year and the exceptional opportunities it now has to deliver substantial, profitable growth going forward.
While COVID-19 continues to present major, ongoing challenges for the global economy, this extraordinary predicament has nevertheless positioned the Group to capture multiple, newly created opportunities in sizeable and wholly unsatisfied, long-term global markets.
Having already provided investors with guidance of £10 million revenue for the current year along with delivery of its first ever quarterly EBITDA profits, DeepVerge recently significantly strengthened its balance sheet through a £10 million (gross) placing to accelerate commercialisation/roll-out/fulfilment/manufacturing scale-up across its three focussed divisions.
Expecting regulatory enforcement to deliver a surge in demand for its unique products and services, most particularly across the Microtox and MicroTrace range, the Microtox® BT nano-optofluidic Rapid Breath Test and Skin Trust Club (‘STC’) home test kits, the Board now expresses a high level of confidence in its ability to deliver a further substantial leap in revenues and profitability for 2022E.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned